EUVIMEDEUVIMED entdecken
Crossref

Explant vs Redo-TAVR After Transcatheter Valve Failure

Gilbert H L Tang, Syed Zaid, Neal S Kleiman, Sachin S Goel, Shinichi Fukuhara, Mateo Marin-Cuartas, Philipp Kiefer, Mohamed Abdel-Wahab, Ole De Backer, Lars Søndergaard, Shekhar Saha, Christian Hagl und 48 weitere

JACC: Cardiovascular Interventions · 2023-04 · 16 (8) · 927-941

DOI: 10.1016/j.jcin.2023.01.376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2023-04. Verfasst von Gilbert H L Tang und 59 weiteren Autor:innen. Beteiligte Einrichtung: Mount Sinai Health System, New York, New York, USA. Electronic address: gilbert.tang@mountsinai.org. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Heart Valve Prosthesis Implantation, Aortic Valve Stenosis, Heart Valve Prosthesis. Die Arbeit wurde bisher 155-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Valve reintervention after transcatheter aortic valve replacement (TAVR) failure has not been studied in detail. OBJECTIVES: The authors sought to determine outcomes of TAVR surgical explantation (TAVR-explant) vs redo-TAVR because they are largely unknown. METHODS: From May 2009 to February 2022, 396 patients in the international EXPLANTORREDO-TAVR registry underwent TAVR-explant (181, 46.4%) or redo-TAVR (215, 54.3%) for transcatheter heart valve (THV) failure during a separate admission from the initial TAVR. Outcomes were reported at 30 days and 1 year. RESULTS: The incidence of reintervention after THV failure was 0.59% with increasing volume during the study period. Median time from index-TAVR to reintervention was shorter in TAVR-explant vs redo-TAVR (17.6 months [IQR: 5.0-40.7 months] vs 45.7 months [IQR: 10.6-75.6 months]; P < 0.001], respectively. TAVR-explant had more prosthesis-patient mismatch (17.1% vs 0.5%; P < 0.001) as the indication for reintervention, whereas redo-TAVR had more structural valve degeneration (63.7% vs 51.9%; P = 0.023), with a similar incidence of ≥moderate paravalvular leak between groups (28.7% vs 32.8% in redo-TAVR; P = 0.44). There was a similar proportion of balloon-expandable THV failures (39.8% TAVR-explant vs 40.5% redo-TAVR; P = 0.92). Median follow-up was 11.3 (IQR: 1.6-27.1 months) after reintervention. Compared with redo-TAVR, TAVR-explant had higher mortality at 30 days (13.6% vs 3.4%; P < 0.001) and 1 year (32.4% vs 15.4%; P = 0.001), with similar stroke rates between groups. On landmark analysis, mortality was similar between groups after 30 days (P = 0.91). CONCLUSIONS: In this first report of the EXPLANTORREDO-TAVR global registry, TAVR-explant had a shorter median time to reintervention, with less structural valve degeneration, more prosthesis-patient mismatch, and similar paravalvular leak rates compared with redo-TAVR. TAVR-explant had higher mortality at 30 days and 1 year, but similar rates on landmark analysis after 30 days.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Aortic Valve ReplacementHeart Valve Prosthesis ImplantationAortic Valve StenosisHeart Valve ProsthesisHumansAortic ValveTreatment OutcomeRisk FactorsRegistriesProsthesis Design

Stichwörter der Autor:innen

TAVR explantationparavalvular leakprosthesis–patient mismatchredo-TAVRstructural valve degenerationsurgical aortic valve replacementtranscatheter aortic valve replacementtranscatheter valve failure

Autor:innen und Institutionen

  • Mount Sinai Health System, New York, New York, USA. Electronic address: gilbert.tang@mountsinai.org.
  • Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA.
  • University of Michigan, Ann Arbor, Michigan, USA.
  • Leipzig Heart Center, Leipzig, Germany.
  • The Heart Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • German Centre for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany.

Zitieren

APA

Tang, G. H. L., Zaid, S., Kleiman, N. S., Goel, S. S., Fukuhara, S., Marin-Cuartas, M., Kiefer, P., Abdel-Wahab, M., De Backer, O., Søndergaard, L., Saha, S., Hagl, C., Wyler von Ballmoos, M., Bhadra, O., Conradi, L., Grubb, K. J., Shih, E., DiMaio, J. M., Szerlip, M., …, & Mack, M. J. (2023). Explant vs Redo-TAVR After Transcatheter Valve Failure. JACC: Cardiovascular Interventions, 16(8), 927-941. https://doi.org/10.1016/j.jcin.2023.01.376

Vancouver

Tang GHL, Zaid S, Kleiman NS, Goel SS, Fukuhara S, Marin-Cuartas M, et al. Explant vs Redo-TAVR After Transcatheter Valve Failure. JACC: Cardiovascular Interventions. 2023;16(8):927-941. doi:10.1016/j.jcin.2023.01.376

BibTeX
@article{Tang2023,
  author = {Tang, Gilbert H L and Zaid, Syed and Kleiman, Neal S and Goel, Sachin S and Fukuhara, Shinichi and Marin-Cuartas, Mateo and Kiefer, Philipp and Abdel-Wahab, Mohamed and De Backer, Ole and Søndergaard, Lars and Saha, Shekhar and Hagl, Christian and Wyler von Ballmoos, Moritz and Bhadra, Oliver and Conradi, Lenard and Grubb, Kendra J and Shih, Emily and DiMaio, J Michael and Szerlip, Molly and Vitanova, Keti and Ruge, Hendrik and Unbehaun, Axel and Kempfert, Jorg and Pirelli, Luigi and Kliger, Chad A and Van Mieghem, Nicholas and Hokken, Thijmen W and Adrichem, Rik and Modine, Thomas and Corona, Silvia and Wang, Lin and Petrossian, George and Robinson, Newell and Meier, David and Webb, John G and Cheung, Anson and Ramlawi, Basel and Herrmann, Howard C and Desai, Nimesh D and Andreas, Martin and Mach, Markus and Waksman, Ron and Schults, Christian C and Ahmad, Hasan and Goldberg, Joshua B and Geirsson, Arnar and Forrest, John K and Denti, Paolo and Belluschi, Igor and Ben-Ali, Walid and Asgar, Anita W and Taramasso, Maurizio and Rovin, Joshua D and Di Eusanio, Marco and Colli, Andrea and Kaneko, Tsuyoshi and Nazif, Tamim N and Leon, Martin B and Bapat, Vinayak N and Mack, Michael J},
  title = {Explant vs Redo-TAVR After Transcatheter Valve Failure},
  journal = {JACC: Cardiovascular Interventions},
  year = {2023},
  volume = {16},
  number = {8},
  pages = {927--941},
  doi = {10.1016/j.jcin.2023.01.376}
}
Kostenlos starten →